Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging pharmacotherapy for treatment of Graves' disease.

Literature DB >> 23234319

Emerging pharmacotherapy for treatment of Graves' disease.

Rebecca S Bahn.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 23234319 PMCID： PMC3902013 DOI： 10.1586/ecp.12.54

Source DB: PubMed Journal: Expert Rev Clin Pharmacol ISSN： 1751-2433 Impact factor: 5.045

× No keyword cloud information.

20 in total

1. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Authors: Rebecca S Bahn Chair; Henry B Burch; David S Cooper; Jeffrey R Garber; M Carol Greenlee; Irwin Klein; Peter Laurberg; I Ross McDougall; Victor M Montori; Scott A Rivkees; Douglas S Ross; Julie Ann Sosa; Marius N Stan
Journal: Thyroid Date: 2011-04-21 Impact factor: 6.568

Review 2. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Authors: Bellur S Prabhakar; Rebecca S Bahn; Terry J Smith
Journal: Endocr Rev Date: 2003-12 Impact factor: 19.871

Review 3. Antithyroid drugs.

Authors: David S Cooper
Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245

4. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.

Authors: Luigi Bartalena; Lelio Baldeschi; Alison J Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten P Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal: Thyroid Date: 2008-03 Impact factor: 6.568

Review 5. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.

Authors: B Rapoport; G D Chazenbalk; J C Jaume; S M McLachlan
Journal: Endocr Rev Date: 1998-12 Impact factor: 19.871

Review 6. Graves' ophthalmopathy.

Authors: Rebecca S Bahn
Journal: N Engl J Med Date: 2010-02-25 Impact factor: 91.245

7. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors: L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal: N Engl J Med Date: 1998-01-08 Impact factor: 91.245

8. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.

Authors: Jane Sanders; Michele Evans; Corrado Betterle; Paul Sanders; Anshu Bhardwaja; Stuart Young; Emma Roberts; Jane Wilmot; Tonya Richards; Angela Kiddie; Kasemsri Small; Hayley Platt; Sara Summerhayes; Rebecca Harris; Magnus Reeve; Graziella Coco; Renato Zanchetta; Shu Chen; Jadwiga Furmaniak; Bernard Rees Smith
Journal: Thyroid Date: 2008-07 Impact factor: 6.568

9. Characterization of thyrotropin receptor antibody-induced signaling cascades.

Authors: Syed A Morshed; Rauf Latif; Terry F Davies
Journal: Endocrinology Date: 2008-08-21 Impact factor: 4.736

10. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.

Authors: Frank Träisk; Leif Tallstedt; Mirna Abraham-Nordling; Tommy Andersson; Gertrud Berg; Jan Calissendorff; Bengt Hallengren; Pavo Hedner; Mikael Lantz; Ernst Nyström; Vesna Ponjavic; Adam Taube; Ove Törring; Göran Wallin; Peter Asman; Göran Lundell
Journal: J Clin Endocrinol Metab Date: 2009-09-01 Impact factor: 5.958

7 in total

Emerging pharmacotherapy for treatment of Graves' disease.

1. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.

Review 2. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Review 3. Antithyroid drugs.

4. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.

Review 5. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies.

Review 6. Graves' ophthalmopathy.

7. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

8. A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.

9. Characterization of thyrotropin receptor antibody-induced signaling cascades.

10. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.

Review 1. Diagnosis and management of Graves disease: a global overview.

2. Graves' disease syndrome: a need for unified therapy.

Review 3. Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Review 4. Graves' orbitopathy: imperfect treatments for a rare disease.

5. Synthetic gene network restoring endogenous pituitary-thyroid feedback control in experimental Graves' disease.

Review 6. Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.

Review 7. Intraorbital Steroid Injection for Active Thyroid Ophthalmopathy.